A subset of patients with hepatocellular carcinoma (HCC) beyond Milan criteria might obtain acceptable survival outcomes after liver transplantation. Living donor liver transplantation (LDLT) has emerged as a feasible alternative to overcome the paucity of donors. In 2001, we started a protocol for LDLT in Child A-B patients with HCC fulfilling a set of criteria-the Barcelona Clinic Liver Cancer (BCLC) expanded criteria-that expanded the conventional indications of transplantation: 1 tumor £ 7 cm, 5 tumors £ 3 cm, and 3 tumors £ 5 cm without macrovascular invasion or downstaging to Milan after locoregional therapies. We present a prospective cohort of 22 patients with BCLC extended indications based on size/number (n 5 17) or downstaging (n 5 5) treated with LDLT between 2001 and 2014. Characteristics of the patients were as follows: median age, 57 years old; males/female, n 5 20/2; Child-Pugh A/B, n 5 16/6; and alpha fetoprotein < 100 ng/mL, n 5 21. Twelve patients received neoadjuvant locoregional therapies. At the time of transplantation, 12 patients had HCC staging beyond Milan criteria and 10 within. Pathological reports showed that 50% exceeded BCLC expanded criteria. Perioperative mortality was 0%. After a median follow-up of 81 months, the 1-, 3-, 5-, and 10-year survival was 95.5%, 86.4%, 80.2%, and 66.8%, respectively. Overall, 7 patients recurred (range, 9-108 months), and the 5-year and 10-year actuarial recurrence rates were 23.8% and 44.4%, respectively. In conclusion, a proper selection of candidates for extended indications of LDLT for HCC patients provide survival outcomes comparable to those obtained within the Milan criteria, but these results need confirmation.
underlying disease and may be applied to patients with advanced liver failure. When strict criteria are applied (the so-called Milan criteria (6) : 1 tumor 5 cm or 3 tumors 3 cm), the 5-year overall survival (OS) reaches 70%. (7, 8) Today, these criteria are included in the Barcelona Clinic Liver Cancer (BCLC) staging system for HCC. (3) (4) (5) Selected patients with HCC beyond the Milan criteria may still obtain acceptable rates of survival after liver transplantation, as pointed out by several studies. (9) (10) (11) (12) (13) These patients generally belong to an intermediate group between the ones with excellent prognosis after liver transplantation (Milan-in patients) and those with indicators of rapid disease progression (macroscopic vascular invasion, diffuse HCC, or extrahepatic disease). Despite some efforts to expand indications of transplant for HCC patients beyond Milan criteria-based on tumor size and number of nodules or successful downstaging after preoperative therapies (9) (10) (11) (12) (13) -clinical practice guidelines have not adopted such extended criteria and the vast majority of transplant centers are still excluding this type of patient from liver transplantation with cadaveric grafts. (3, 4, 14) The 2010 Consensus Conference on liver transplantation for HCC recommends living donor liver transplantation (LDLT) as an ethically acceptable alternative for patients with expected 5-year survival comparable to that of patients receiving a cadaveric graft, although the strength of recommendation is weak, because of the different approaches between transplant centers. (14) From this point of view, LDLT represents an alternative option for patients with HCC beyond the Milan criteria because it offers them a curative treatment without affecting the pool of donors for patients enlisted for deceased liver transplantation.
In 2000, our group began a local program of LDLT, and in March 2001, it was expanded following a specific protocol (15) allowing the enlistment of HCC patients beyond Milan criteria as per Table 1 . The main objective of this pilot study was to assess the survival and recurrence rates after LDLT in this type of patients. We report herein the results of a pilot prospective study including 22 HCC patients with extended indications treated by LDLT and followed for a longterm period.
Patients and Methods
Between March 2000 and December 2014, 97 patients were effectively transplanted in the LDLT program of our Liver Transplantation Unit following a previously published protocol. (16) The study protocol was approved by the ethics committee of the Hospital Clinic of Barcelona. Indication for transplantation was based on HCC diagnosis in 39 (40.2%) of these patients, 22 of them being accepted according to expanded HCC criteria applied at our institution since March 2001 (Table 1) . (15) These 22 patients represent our study population.
PATIENTS

Recipients and Donor Selection
The complete preoperative study and the donation planning were done according to the Spanish Law of Organ Donation, as previously described. (16) Detailed explanations related to the procedure, its complexity, and possible complications are critical parts of the process for both the donor and the recipient. (17) Inclusion criteria of the recipients were as follows: diagnosis of HCC according to the European Association for the Study of the Liver and American Association for the Study of Liver Diseases (AASLD) guidelines, (3, 4, 18) age between 18 and 70 years, BCLC expanded criteria for LDLT (see Table 1 ), Eastern Cooperative Oncology Group (ECOG) performance status 0, and Child-Pugh A or B class. Preoperative HCC staging workup included 4-phase abdominal computed tomography (CT) scan or magnetic resonance imaging (MRI), thorax X-ray, and bone scintigraphy. Size of the main nodule was established according to either CT scan or MRI, whereas additional nodules would require 2 coincidental imaging techniques if the size was between 1 and 2 cm, and 1 imaging technique if the size was >2 cm, showing the radiological hallmark of HCC. Alpha fetoprotein (AFP) plasma levels > 1000 ng/mL required further workup to discard advanced disease (laparoscopic ultrasound [US] and body CT scan). Status of vascular invasion was defined by Doppler US and/or MRI. Doubts regarding the nature of a portal thrombosis were ruled out by biopsy studies.
Recipient exclusion criteria were as follows: patients older than 70 years, single tumor larger than 7 cm or smaller but with satellites (defined as any HCC 2 cm within a 2-cm ring around the main nodule), multinodular tumor beyond inclusion criteria, diffuse HCC, neoplastic vascular invasion of any vessel, lymph node involvement or extrahepatic tumor disease, Child-Pugh class C, or ECOG performance status > 0. In the case of recipients aged between 66 and 70 years old, additional cardiovascular (normal cardiac stress test), respiratory (low risk of complications by pulmonary function testing), and renal test (normal renal function) were conducted. Recipient evaluation includes the same parameters as in conventional liver transplantation. Donor selection criteria included age between 18 and 55 years, ABO group compatibility with the recipient, healthy individuals with graft-to-body-weight ratio (GBWR) higher than 0.8%, and normal psychological workup. All donors signed informed consent in front of a judge according with the law. Workup for donors has been reported in previous studies of our group. (16, 19) A key aspect of this workup is the analysis of graft vascular and biliary distribution, and graft volume using CT scan and MRI-angiography, which can anticipate the complexity of the surgery and eventually even contraindicate the procedure. (19, 20) Donors with liver steatosis by imaging techniques and normal blood analysis were only considered in cases where liver biopsy demonstrates <20% of liver steatosis.
Feasibility
The protocol execution contained 2 parts: the feasibility part (9 patients) and the complete final pilot study (up to 22 patients). The feasibility run-in part involved the evaluation of the first 9 LDLT patients, and the results have been previously communicated. (21) In this part, we assessed whether the protocol was feasible, the number of potential patients emerging out of the total HCC patients visited, the number of donors per candidate recipient, and the reasons for accepting/rejecting the candidate. The study team estimated that the results obtained at this cutoff point were adequate, and thus agreed proceeding to the completion of the study with an initial target sample size of 20 patients. For the purpose of the current report, the recruitment ends at December 2014 and the follow-up expands to February 2017.
Patient Characteristics
Baseline characteristics of the patients before LDLT are depicted in Table 2 . For every recipient, data regarding age, sex, etiology and preoperative stage of hepatic disease, treatment performed before LDLT (as neoadjuvant or downstaging therapy), pretransplant and posttransplantation liver function, AFP levels before and after LDLT, preoperative radiological stage, explant histological result, number and type of intraoperative and postoperative complications according to the Clavien-Dindo scale, (22) intensive care unit (ICU) and hospital stay, type of immunosuppression, follow-up, recurrence, and death were prospectively recorded in a database and analyzed.
METHODS
Locoregional Therapies Previous to LDLT
In 12 (54.5%) patients, locoregional therapies were performed (11 patients treated with transarterial chemoembolization [TACE] and 1 patient with percutaneous ethanol injection [PEI]; Fig. 2 ). In 5 of these patients, downstaging (ie, remaining within Milan criteria in 2 consecutive radiological assessments) allowed inclusion in the expanded criteria used at our center. In all the remaining cases, patients were already meeting 1 of the "size and/or number" expanded criteria.
Surgical Intervention and Postoperative Period
The LDLT procedure followed the protocol of our Liver Transplantation Unit, as previously described. (16, 19, 20) All 22 transplants were performed using the right liver lobe. Surgical procedure details, intraoperative incidences, ICU, hospital stay, postoperative complications, and immunosuppression therapy used were also recorded. Postoperative immunosuppression regimens followed a standardized protocol. In principle, the immediate posttransplant immunosuppression treatment includes methylprednisolone in descending dosage along with calcineurin inhibitors (tacrolimus, but cyclosporine in patients with pretransplant diabetes). Mycophenolate mofetil is generally used until reaching therapeutic levels of calcineurin inhibitors. Mammalian target of rapamycin treatments, such as everolimus, were used in 4 patients.
Follow-up and Assessment of Recurrence
After being discharged, all patients were followed monthly in the outpatient clinic until 90 days from LDLT, every other month during the first year after LDLT, and every 3 months until 2 years from the transplantation. In addition to conventional clinical parameters (symptoms related to the tumor or hepatic decompensation), radiological explorations (US, CT, or MRI) and liver function assessment were performed in each outpatient visit during the first 2 years. Followup beyond this time period with blood test and radiological imaging was based on clinical criteria.
Pre-LDLT Radiological Examination and Histological Explant Analysis
Median time between donor and recipient evaluation (including treatment/downstaging) and transplant was 4.5 months. Assessment of pre-LDLT radiological examination included number, site, and maximum diameter of tumor nodules; viable tumors after neoadjuvant therapy; and satellite nodules. The pathological report of the explanted liver includes the following information: description of number, location, and maximum diameter of all tumor nodules; differentiation degree; presence of microvascular or macrovascular invasion; and satellite nodules.
STATISTICAL ANALYSIS
Epidemiological and analytical quantitative data are expressed as mean 6 standard deviation. Follow-up length, OS, and time to recurrence are expressed as median (range). Probability curves of patient and graft survival were calculated according to the Kaplan-Meier method and compared by the Mantel-Cox test.
Differences between qualitative variables were assessed by Fisher's exact test; differences between quantitative variables were analyzed by t test. All the calculations were performed by using SPSS Statistics, version 22 (IBM, Armonk, NY).
Results
FEASIBILITY
The feasibility run-in part of the study was conducted between March 2001 and December 2003. (21) During this time period, 381 patients with HCC visited our BCLC program, among whom 142 (37%) received either resection (22 patients), orthotopic liver transplantation (OLT; 36 patients), or percutaneous ablation (84 patients). A total of 34 (9%) patients were considered for the specific protocol for LDLT as per the BCLC expanded criteria. Finally, 205 patients received locoregional or symptomatic treatment according to guidelines. (18) No systemic therapy with sorafenib was available at that time as standard of care since benefits of this therapy were reported afterward. (23) Among 34 patients evaluated for LDLT, 13 did not find/require any donor candidate (recipient refused the procedure, n 5 10; HCC progression during evaluation, n 5 2; recipient unable to identify a donor, n 5 1), whereas 21 provided 57 potential donors. Among these patients, 12 recipients had an inadequate donor (20 donors evaluated: blood ABO incompatibility, (5) liver steatosis, (6) or medical contraindications. (9) Finally, 9 patients received a LDLT during this run-in period, representing 26.5% of the 34 receptors evaluated, and 2.6% of the total HCC patients visited during this time period. All these data were considered acceptable for the feasibility/run-in period, and thus the protocol was approved for completion, with a final recruitment number of 22 patients.
LOCOREGIONAL TREATMENT AND TUMOR STAGE PRIOR TO LDLT
Out of the 22 final candidates with BCLC extended indications, 17 patients were included in the protocol due to extended "size and number" criteria and 5 due to downstaging to Milan criteria from any previous size (Fig. 2) . All patients achieving downstaging to Milan criteria were treated with TACE (overall, median time on downstaging was 134 days). Among 17 additional patients meeting "size and number" criteria, 7 received treatment (6 with TACE and 1 with PEI) as a bridge therapy while waiting to complete pretransplant evaluation in patients with long evaluation times. Thus, overall 12 patients were ultimately treated with neoadjuvant locoregional treatment while waiting for LDLT or to achieve downstaging. Out of the 12 patients treated, 5 (22.7%) achieved complete response, 6 (27.3%) partial responses, and 1 patient showed stable disease. Four patients who responded to treatment presented hepatic recurrence before LDLT. Median time between last radiological exploration (MRI in 19 patients and CT scan in 3 patients) and LDLT was 59 days. At the last imaging technique prior LDLT, 10 out of 22 patients (45.5%) presented with a tumor stage inside Milan criteria.
SURGICAL DATA
Mean GBWR estimated before surgery was 1.26% 6 0.32%, whereas the actual GBWR calculated with the graft lobe weight was 1.09% 6 0.27%. Total surgery time between donor and recipient intervention was 417 6 83 minutes. Mean final portal and arterial flow were 1552 6 520 mL and 189 6 101 mL, respectively. A total of 11 patients required red blood cell (RBC) transfusion during surgery (mean of 3.9 6 3.1 RBC concentrates/transfused patient), 14 plasma transfusion (mean of 1714 6 738 mL/transfused patient), and 3 platelets transfusion (mean of 6.4 6 5.5 platelet units/transfused patient). No patient developed small-for-size syndrome.
EXPLANT HISTOLOGICAL RESULTS
Explant histological characteristics are depicted in Table  3 . Median size of the main nodule was 32.4 mm, 19 patients presented with multinodular disease, 10 (45.5%) microvascular invasion, and 9 (40.9%) satellites. In terms of pathological tumor staging, 4 (18.2%) patients were inside Milan criteria, 7 (31.8%) patients were beyond Milan criteria but inside our BCLC expanded criteria, and 11 (50.0%) patients were beyond these criteria. Overall, the number of tumors in the histological examination was higher than in the last radiological imaging prior to LDLT (5 patients in explant versus 3 patients in MRI/CT before LDLT).
POSTOPERATIVE PERIOD AND FOLLOW-UP
Perioperative complications for donors and recipients are summarized in Table 4 . Median ICU stay and total hospital stay for recipients were 6.1 6 4.3 days (range, 3-24 days) and 27.7 6 22.6 days (range, 9-101 days), respectively. Medical complications for the recipient occurred in 12 (54.5%) patients, and surgical complications occurred in 16 (72%) patients. Among the latter, 
LLOVET ET AL. LIVER TRANSPLANTATION, March 2018
biliary leak (13 patients) resulting in surgical treatment in 8 patients was the most notorious. Perioperative mortality was 0%. Regarding longterm complications, 9 patients presented with hepatitis C virus (HCV)-induced cirrhosis, and there was 1 patient with chronic rejection. No indication for retransplantation was made. From the donor standpoint, 5 (22.7%) patients presented perioperative complications, 1 of which was Clavien-Dindo grade IIIb (22) (bile leak which required surgical reintervention).
OVERALL SURVIVAL
After a median follow-up of 81 months (range 7-188 months), 8 patients died, 4 of whom died due to HCC recurrence (Table 5 ). Actuarial probability of survival at 1, 3, 5, and 10 years was 95.5%, 86.4%, 80.2%, and 66.8%, respectively (Fig. 3) .
RECURRENCE RATES
At the end of follow-up, 7 patients recurred: 2 only in the liver (91 and 62 months after LDLT), 1 in the liver and bone (at 9 months), 1 in the form of a liver tumor and peritoneal carcinomatosis (at 58 months), 1 in the liver and mediastinal lymph nodes (at 57 months), 1 in the liver and adrenal gland (54 months), and 1 as bilateral adrenal gland (9 years after LDLT). Four patients died within the first year after presenting with recurrence, whereas 3 patients (liver recurrence with NOTE: Data are given as n (%) and mean 6 standard deviation, unless otherwise noted. *5 patients with both biliary leak and stenosis. mediastinal lymph nodes at 57 months, liver recurrence with adrenal gland metastasis at 54 months, and another with adrenal gland metastases) are still alive. All 7 patients were initially HCV positive, and 5 of them had cirrhosis recurrence confirmed by histology. Explant histology showed that 6 of the patients were outside BCLC extended criteria, with microvascular invasion in 5 patients and satellites in 3 patients. One of the patients was inside BCLC expanded criteria but presented with microvascular invasion and satellites. No relationship was found between the recurrence and the type of immunosuppression. Overall, the actuarial probability of recurrence at 5 and 10 years was 23.8%
and 44.4%, respectively (Fig. 4) . One recurrence was detected 1 year after the patient had received HCV direct-acting antivirals. Two patients were treated with sorafenib, and 4 are currently dead due to tumor progression.
PROGNOSTIC FACTORS
Better OS was observed for patients who were within the Milan criteria (n 5 10) in the last radiological exploration before LDLT when compared with patients who were beyond these criteria (n 5 12) at the same time period (5-year and 10-year survival 90.0% and 90.0% versus 70.0% and 52.1%, respectively; P 5 0.046; Fig. 5 ). Survival was not significantly influenced by any other variable related to preoperative stage, histological explant analysis, or intraoperative and postoperative complications.
Discussion
The incidence of HCC is steadily growing globally, but just approximately 30%-40% of those patients are amenable for potential curative therapies. (1) (2) (3) (4) (5) Benefits from OLT are clearly achieved when applying the Milan criteria, which have been widely adopted by clinical practice guidelines of management of HCC, (3, 4) guidelines of liver transplantation, (14) and by the US United Network for Organ Sharing. Recent meta-analysis of patients undergoing OLT for HCC within Milan criteria confirm that 5-year and 10-year survival rates of 70% and 50%, respectively, are consistently reported. (7) Nonetheless, the applicability of OLT in those patients is limited due to the shortage of donors, a problem that has not been solved during the past 2 decades. As a result, a proportion of patients die on the waiting list or are not even considered for OLT. In parallel, different studies have shown 5-year survival rates >50% in selected patients with HCC beyond Milan criteria submitted to liver transplantation when compared with their counterparts within Milan criteria, (9) (10) (11) (12) (13) posing the question of whether Milan criteria are too strict for current radiological standards compared with those of 1996. (6) LDLT can be a thorough alternative to OLT in referral centers because it is not limited to the shortage of donors. (14, 24) This strategy appears appealing because there is no prejudice for other candidates to OLT on the waiting list, mostly patients with cirrhosis with end-stage disease. Notably, guidelines have emphasized that from the ethical perspective, the concept of double equipoise (meaning a balance between the risk of a healthy donor and the benefit for the HCC patient) should be considered. (14) The risk of mortality for a donor of the right lobe is reported to be approximately 0.17%. (25) LDLT has been proposed in 2 areas: for patients on the waiting list of OLT and for those exceeding Milan criteria. A recent meta-analysis has pointed out that outcomes for LDLT and OLT are similar in terms of survival (26) when considering Milan-in-only patients. The most burning question, however, and the one addressed in the current study, is whether LDLT is safe and efficacious in patients exceeding Milan criteria. Such patients are mostly categorized as BCLC stage A or B and are treated with chemoembolization in most instances, achieving median survival rates ranging from 30 to 45 months. (3, 4) In some series, however, median survival 50 months has been reported in outstanding candidates, (27) which provides a framework for comparing the outcomes reported herein with LDLT. So far, expansion of criteria has been mostly based on tumor size and number, in the case of University of California, San Francisco, (12) and up-to-7 criteria, (9) tumor volume, (28) or even molecular characteristics based on gene expression. (29) Finally, AFP has also been incorporated into the selection of candidates in France (30) and Canada, (31) where patients with AFP > 1000 ng/dL are excluded from transplant due to poor outcomes.
We herein present the outcome data of a pilot prospective cohort study with predefined modest expansion criteria previously reported. (15) These criteria are based on size and number (single 7 cm, 3 nodules 5 cm, and 5 nodules 3 cm), or tumor behavior (downstaging to Milan after locoregional therapies), absence of tumor-related symptoms (ECOG 0), and well-preserved liver function (Child A or B). Almost all patients underwent transplantation with AFP < 100 ng/mL, and there were no patients with AFP > 1000 ng/mL. Results of this pilot study reveal potential implications on the future management of HCC for a small population of patients with LDLT due to the survival outcome achieved.
Survival data were remarkable. OS at 5 and 10 years was 80.2% and 66.8%, after a median follow-up of approximately 81 months. These figures compare well with those reported for deceased liver donor transplantation, (7) which is the master framework for any comparison. (14) Even when further analyzing outcomes in patients maintaining beyond Milan criteria in the last radiological examination before LDLT-despite the small sample size (12 patients)-the 5-and 10-year probability of survival is still approximately 70% and 50%, respectively. Notably, the current European report of liver transplantation for HCC including 19,000 patients, within/beyond Milan criteria, reports a 10-year survival rate of 50%. (32) Survival also outperforms the outstanding median of 50 months reported after TACE in selected patients. (27) Thus, overall the survival figures fit well with the preplanned expectations, and the accepted outcomes for proposing LDLT in HCC.
On the other hand, the actuarial probability of recurrence at 5 and 10 years was 23.8% and 44.4%, respectively. As expected, the majority of the patients showed a pathological staging beyond BCLC extension criteria, mostly as a result of additional small nodules not detected in preoperative imaging staging. In fact, 6 out of 7 patient recurrences occurred in patients with pathological staging beyond BCLC extension criteria. Although 5-year recurrence rates are slightly higher than the ones reported for patients within Milan (23.8%), 10-year recurrent data require some analysis. The latter figure is difficult to interpret because almost no data have been reported in terms of 10-year recurrence rate after liver transplantation. Interestingly, 1 of the late recurrences was detected after 1 year of HCV treatment with direct-acting antiviral agents, which adds further data in the controversy on the potential increase of HCC recurrence with LIVER TRANSPLANTATION, Vol. 24, No. 3, 2018 LLOVET ET AL.
these agents. (33) In terms of potential chemopreventive intervention, a recent randomized trial failed to demonstrate benefits in terms of recurrence-free survival for sirolimus-based immunosuppression treatment in preventing recurrence after HCC transplant. (34) Thus, so far only candidate selection might diminish this figure. (9) Overall, the results are positive, but they certainly need to be validated prior to being considered for consensus criteria. In addition, they should be carefully interpreted. First, applicability of LDLT in our environment was low, because we were able to effectively operate on only 22 patients within a 14-year period. In fact, applicability of LDLT was explored in the first run-in part of the study. (21) Out of a total of 381 patients with HCC visited during a 22-month period, only 34 (9%) were potential candidates for LDLT, and among those, only 9 were effectively transplanted, representing 25% of those evaluated and approximately 2.6% of the total HCC population of a center of reference. Second, considering the concept of double equipoise, we need to emphasize that 5 (22%) donors presented with postoperative complications, 1 of whom required surgical reintervention. This complication rate is below the previously reported rate on a large series of cases. (35) Recipient complications were within the expected range reported, with no perioperative mortality. Third, a proportion of patients with extended indications actually presented downstaging, meaning a preoperative staging prior to transplant of Milan-in after locoregional therapy. (14, 34) This treatment was adopted in order to achieve downstaging to Milan (median of 134 days of downstaging before LDLT) as the primary inclusion criteria in 5 patients or because they were treated while waiting for the completion of the preoperative evaluation, which as a whole lasted for 4.5 months. These considerations should be taken into account for tempering the potential excitement when analyzing the raw outcome obtained in the global context of LDLT. (36, 37) Notably, the recently reported AASLD guidelines suggest, based on low evidence, that patients beyond Milan criteria should be considered for transplantation after successful downstaging into the Milan criteria. (38) In conclusion, our study adds a valuable piece of information in the context of the effectiveness of LDLT for extended indications of HCC. This prospective study reports acceptable survival outcomes comparable to those obtained within the Milan criteria, thus supporting a minor expansion in the selection criteria of HCC candidates for LDLT. Even though the 10-year recurrence is high, the outcome is counterbalanced by the longterm transplant benefit achieved. (39) We propose, therefore, pursuing these extended criteria in other centers of excellence because these results need further prospective confirmation before being adopted by clinical practice guidelines.
